North Carolina-based NOVA Thin Film Pharmaceuticals (NTFP) has started operations of its soluble thin film.
The drug delivery company NTFP commercialises its products using its patented DepoFilm technology, which represents the thin film technology 2.0.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Dr Richard Fuisz along with Joseph Fuisz invented the issued DepoFilm patents.
The technology is designed to help overcome the challenges faced with conventional wet-cast thin film, according to the company. It also allows development of innovative new product concepts.
Dr Fuisz said: “The beauty of DepoFilm lies in its elegant simplicity, and the move of thin film manufacture into a single stage integrated manufacturing process from film formation to final primary packaging, together with the virtual elimination of yield issues that have bedeviled wet-cast manufacturers.
“This new effort represents an important contribution to drug delivery.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataNTFP operates a manufacturing facility in Wilmington located at the company’s partner and lead investor Quality Chemical Laboratories’ (QCL) manufacturing and laboratory facilities.
It also has a research and development facility in Greensboro.
NTFP chief executive officer Joseph Fuisz said: “NOVA Thin Film is founded on a simple premise: that existing film technology is too complex and too costly to meet market needs.
“Thin film offers valuable benefits to patients and NOVA Thin Film’s superior technology will address formulation, scale up and cost challenges.”
